We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Compugen (CGEN - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Compugen is a member of the Medical sector. This group includes 1089 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Compugen is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CGEN's full-year earnings has moved 8.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, CGEN has gained about 9.2% so far this year. At the same time, Medical stocks have lost an average of 6.3%. This means that Compugen is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Evogene (EVGN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 4.3%.
The consensus estimate for Evogene's current year EPS has increased 6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Compugen is a member of the Medical - Biomedical and Genetics industry, which includes 528 individual companies and currently sits at #61 in the Zacks Industry Rank. Stocks in this group have lost about 19.6% so far this year, so CGEN is performing better this group in terms of year-to-date returns. Evogene is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Compugen and Evogene. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Compugen (CGEN - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Compugen is a member of the Medical sector. This group includes 1089 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Compugen is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CGEN's full-year earnings has moved 8.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, CGEN has gained about 9.2% so far this year. At the same time, Medical stocks have lost an average of 6.3%. This means that Compugen is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Evogene (EVGN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 4.3%.
The consensus estimate for Evogene's current year EPS has increased 6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Compugen is a member of the Medical - Biomedical and Genetics industry, which includes 528 individual companies and currently sits at #61 in the Zacks Industry Rank. Stocks in this group have lost about 19.6% so far this year, so CGEN is performing better this group in terms of year-to-date returns. Evogene is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Compugen and Evogene. These stocks will be looking to continue their solid performance.